DK1021194T3 - Ny forbedret formulering til behandling af osteoporose - Google Patents

Ny forbedret formulering til behandling af osteoporose

Info

Publication number
DK1021194T3
DK1021194T3 DK98948029T DK98948029T DK1021194T3 DK 1021194 T3 DK1021194 T3 DK 1021194T3 DK 98948029 T DK98948029 T DK 98948029T DK 98948029 T DK98948029 T DK 98948029T DK 1021194 T3 DK1021194 T3 DK 1021194T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
treatment
new improved
improved formulation
formulation
Prior art date
Application number
DK98948029T
Other languages
English (en)
Inventor
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1021194T3 publication Critical patent/DK1021194T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK98948029T 1997-10-10 1998-10-05 Ny forbedret formulering til behandling af osteoporose DK1021194T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703691A SE9703691D0 (sv) 1997-10-10 1997-10-10 Pharmaceutical compositions
PCT/SE1998/001790 WO1999018972A1 (en) 1997-10-10 1998-10-05 New improved formulation for treatment of osteoporosis

Publications (1)

Publication Number Publication Date
DK1021194T3 true DK1021194T3 (da) 2003-09-01

Family

ID=20408561

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948029T DK1021194T3 (da) 1997-10-10 1998-10-05 Ny forbedret formulering til behandling af osteoporose

Country Status (14)

Country Link
US (1) US6372728B1 (da)
EP (2) EP1310259A3 (da)
JP (1) JP2001519398A (da)
AR (1) AR015946A1 (da)
AT (1) ATE240107T1 (da)
AU (1) AU9469198A (da)
DE (1) DE69814656T2 (da)
DK (1) DK1021194T3 (da)
ES (1) ES2200378T3 (da)
PT (1) PT1021194E (da)
SA (1) SA98190775A (da)
SE (1) SE9703691D0 (da)
WO (1) WO1999018972A1 (da)
ZA (1) ZA988886B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579860B1 (en) * 1998-12-25 2003-06-17 Toray Industries, Inc. Interleukin-6 production inhibitors
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
SI1591122T1 (sl) * 2000-06-20 2013-02-28 Novartis Ag Postopek za aplikacijo bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
CA2452056C (en) * 2001-07-02 2011-11-01 Elan Corporation, Plc. Compositions of bioactive material particles dispersed in a continuous solid encapsulating material
CN1633300A (zh) * 2002-02-14 2005-06-29 山之内制药株式会社 透皮制剂
JP4546704B2 (ja) * 2002-02-14 2010-09-15 救急薬品工業株式会社 経皮投与製剤
ES2532393T3 (es) 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
ITMI20032175A1 (it) * 2003-11-11 2005-05-12 Tiberio Bruzzese Formulazioni farmaceutiche di bisfosfonati destinate
US20050182028A1 (en) * 2004-02-13 2005-08-18 Chen Chih-Ming J. Pharmaceutical formulation for oral delivery of bisphosphates
DK1753395T3 (da) * 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006105615A1 (en) * 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
CN101437522A (zh) * 2006-04-07 2009-05-20 默里昂研究Ⅲ有限公司 包含增强剂的固体口服剂型
WO2007132714A1 (ja) * 2006-05-16 2007-11-22 The Nisshin Oillio Group, Ltd. 骨密度増加剤
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
WO2009137078A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL175882C (nl) * 1977-03-28 Procter & Gamble Farmaceutisch preparaat, dat een verbinding met ontstekingtegengaande werking bevat.
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
EP0416689B1 (en) * 1989-09-06 1995-11-29 Merck & Co. Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
JPH08507078A (ja) 1993-02-17 1996-07-30 スミスクライン・ビーチャム・コーポレイション 治療用ペプチド含有のミクロエマルジョン
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon

Also Published As

Publication number Publication date
DE69814656T2 (de) 2004-03-25
US6372728B1 (en) 2002-04-16
SE9703691D0 (sv) 1997-10-10
DE69814656D1 (de) 2003-06-18
ATE240107T1 (de) 2003-05-15
AR015946A1 (es) 2001-05-30
JP2001519398A (ja) 2001-10-23
SA98190775A (ar) 2005-12-03
PT1021194E (pt) 2003-09-30
ZA988886B (en) 1999-04-12
EP1310259A3 (en) 2003-05-21
AU9469198A (en) 1999-05-03
EP1021194A1 (en) 2000-07-26
EP1021194B1 (en) 2003-05-14
EP1310259A2 (en) 2003-05-14
ES2200378T3 (es) 2004-03-01
WO1999018972A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
DK1021194T3 (da) Ny forbedret formulering til behandling af osteoporose
DK1032566T5 (da) Fremgangsmåde til fremstilling af citalopram
NO980177D0 (no) Flytende gonadotropin-holdige formuleringer
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
IS2325B (is) Örgerðar samsetningar epleróns
DK200200116U4 (da) Mundhygiejnepræparat til behandling af halitosis
DK1028727T3 (da) Bestanddele til forögelse af hudpenetration
ID25533A (id) Formulasi 2-metil-tieno-benzodiazepin
FI972701A (fi) Menetelmä päätelaitteiden käytön rajoittamiseksi
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
IS4812A (is) Samsett meðferð fyrir beingisnun
DK199800837A (da) Anlæg til behandling af emner
NO993298L (no) Ny fremgangsmÕte
DK1027315T3 (da) Fremgangsmåde til fremstilling af n-butanol
DK1028960T3 (da) Fremgangsmåde til fremstilling af thiazolidinedion
DK1702623T3 (da) Anvendelse af interferon-gamma til behandling af hjertehypertrofi
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
NO995796D0 (no) Ny fremgangsmåte
DK0946514T3 (da) Fremgangsmåde til fremstilling af n-substituerede 3-hydroxypyrazoler
EE200000055A (et) Protsess tsüklopropüülatsetüleeni valmistamiseks
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DK0973769T3 (da) Fremgangsmåde til fremstilling af eprosartan
EE9900594A (et) Uued astmavastased ravimkoostised
DK0970073T3 (da) Fremgangsmåde til fremstilling af eprosartan